ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) has initiated closing logistics for its previously announced acquisition of Alimera Sciences (Nasdaq: ALIM). The company expects to complete and announce the closing of the acquisition today, September 16, 2024, subject to the satisfaction or waiver of any remaining customary closing conditions. This strategic move signifies a significant expansion for ANI Pharmaceuticals, potentially enhancing its market position and product portfolio. The acquisition of Alimera Sciences, a company known for its focus on retinal diseases, could bring new opportunities and synergies to ANI's existing pharmaceutical operations.
Positive
- Expansion of ANI Pharmaceuticals' market presence through strategic acquisition
- Potential enhancement of product portfolio with Alimera Sciences' retinal disease treatments
- Imminent completion of the acquisition, indicating smooth transaction progress
Negative
- None.
News Market Reaction – ANIP
In the trading session that priced this news, ANIP declined 3.95%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM).
The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. ANI is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
This communication, and the documents to which it refers you, contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the parties’ expectations or beliefs concerning future events, including the timing of the transaction and other information relating to the transaction. Forward-looking statements include information concerning the expected completion and timing of the transaction and other information relating to the transaction. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “forecasts,” “should,” “estimates,” “contemplate,” “future,” “goal,” “potential,” “predict,” “project,” “projection,” “may,” “will,” “could,” “should,” “would,” “assuming” and similar expressions are intended to identify forward-looking statements. You should read statements that contain these words carefully. They discuss ANI’s and/or Alimera’s future expectations or state other forward-looking information and may involve known and unknown risks over which the parties have no control. Forward-looking statements speak only as of the date of this communication or the date of any document incorporated by reference in this document. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are described in the parties’ respective SEC reports. Except as required by applicable law or regulation, neither party undertakes to update these forward-looking statements to reflect future events or circumstances.
Investor and/or Media Contacts:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
